Immunome Statistics
Total Valuation
Immunome has a market cap or net worth of $2.53 billion. The enterprise value is $1.97 billion.
Important Dates
The last earnings date was Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunome has 113.25 million shares outstanding. The number of shares has increased by 46.00% in one year.
| Current Share Class | 113.25M |
| Shares Outstanding | 113.25M |
| Shares Change (YoY) | +46.00% |
| Shares Change (QoQ) | +19.18% |
| Owned by Insiders (%) | 1.16% |
| Owned by Institutions (%) | 108.51% |
| Float | 108.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 635.22 |
| Forward PS | 142.61 |
| PB Ratio | 4.25 |
| P/TBV Ratio | 4.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 491.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.68, with a Debt / Equity ratio of 0.01.
| Current Ratio | 21.68 |
| Quick Ratio | 21.26 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -50.14% and return on invested capital (ROIC) is -31.63%.
| Return on Equity (ROE) | -50.14% |
| Return on Assets (ROA) | -29.72% |
| Return on Invested Capital (ROIC) | -31.63% |
| Return on Capital Employed (ROCE) | -38.63% |
| Weighted Average Cost of Capital (WACC) | 15.86% |
| Revenue Per Employee | $19,490 |
| Profits Per Employee | -$1.09M |
| Employee Count | 206 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +161.86% in the last 52 weeks. The beta is 2.11, so Immunome's price volatility has been higher than the market average.
| Beta (5Y) | 2.11 |
| 52-Week Price Change | +161.86% |
| 50-Day Moving Average | 22.11 |
| 200-Day Moving Average | 18.66 |
| Relative Strength Index (RSI) | 52.27 |
| Average Volume (20 Days) | 988,578 |
Short Selling Information
The latest short interest is 18.66 million, so 16.48% of the outstanding shares have been sold short.
| Short Interest | 18.66M |
| Short Previous Month | 18.60M |
| Short % of Shares Out | 16.48% |
| Short % of Float | 17.22% |
| Short Ratio (days to cover) | 20.68 |
Income Statement
In the last 12 months, Immunome had revenue of $4.01 million and -$224.59 million in losses. Loss per share was -$2.34.
| Revenue | 4.01M |
| Gross Profit | -182.78M |
| Operating Income | -228.81M |
| Pretax Income | -224.59M |
| Net Income | -224.59M |
| EBITDA | -226.35M |
| EBIT | -228.81M |
| Loss Per Share | -$2.34 |
Full Income StatementBalance Sheet
The company has $582.69 million in cash and $3.69 million in debt, with a net cash position of $579.00 million or $5.11 per share.
| Cash & Cash Equivalents | 582.69M |
| Total Debt | 3.69M |
| Net Cash | 579.00M |
| Net Cash Per Share | $5.11 |
| Equity (Book Value) | 588.69M |
| Book Value Per Share | 5.20 |
| Working Capital | 566.90M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$196.50 million and capital expenditures -$9.02 million, giving a free cash flow of -$205.52 million.
| Operating Cash Flow | -196.50M |
| Capital Expenditures | -9.02M |
| Depreciation & Amortization | 2.46M |
| Net Borrowing | n/a |
| Free Cash Flow | -205.52M |
| FCF Per Share | -$1.81 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -5,698.83% |
| Pretax Margin | -5,593.85% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunome does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -46.00% |
| Shareholder Yield | n/a |
| Earnings Yield | -8.81% |
| FCF Yield | -8.06% |
Analyst Forecast
The average price target for Immunome is $35.36, which is 58.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.36 |
| Price Target Difference | 58.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 94.69% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Immunome has an Altman Z-Score of 25.46 and a Piotroski F-Score of 2.
| Altman Z-Score | 25.46 |
| Piotroski F-Score | 2 |
